Mannucci P M, Vicente V, Vianello L, Cattaneo M, Alberca I, Coccato M P, Faioni E, Mari D
Blood. 1986 Apr;67(4):1148-53.
The synthetic vasopressin derivative desmopressin (DDAVP) shortens a prolonged bleeding time (BT) in patients with uremia, congenital platelet dysfunction, and von Willebrand disease. To establish the limits of the clinical usefulness of DDAVP, a controlled randomized study was carried out in 53 patients and ten volunteers with different conditions that have in common a prolonged BT. DDAVP significantly shortened the BT in 21 cirrhotics (P less than .01), in eight patients with unclassified prolonged BT (P less than .05) and in ten volunteers taking the antiplatelet drugs aspirin (P less than .05) and ticlopidine. The BT changes were not statistically significant in 15 patients with severe thrombocytopenia nor in nine with congenital platelet dysfunction, even though a few patients with storage pool deficiency responded with a marked BT shortening. Our findings indicate that DDAVP might be given when biopsies or other surgical procedures must be carried out in patients with prolonged BT. However, the compound is often ineffective in patients with thrombocytopenia or congenital platelet dysfunction.
合成血管加压素衍生物去氨加压素（DDAVP）可缩短尿毒症、先天性血小板功能障碍和血管性血友病患者延长的出血时间（BT）。为确定DDAVP临床应用的限度，我们对53例患者和10名志愿者进行了一项对照随机研究，这些患者和志愿者患有不同疾病，但都有BT延长的情况。DDAVP显著缩短了21例肝硬化患者的BT（P＜0.01）、8例未分类的BT延长患者的BT（P＜0.05）以及10名服用抗血小板药物阿司匹林（P＜0.05）和噻氯匹定的志愿者的BT。15例严重血小板减少症患者和9例先天性血小板功能障碍患者的BT变化无统计学意义，尽管少数储存池缺陷患者的BT明显缩短。我们的研究结果表明，当必须对BT延长的患者进行活检或其他外科手术时，可以使用DDAVP。然而，该化合物对血小板减少症或先天性血小板功能障碍患者通常无效。
